目的:观察扶正祛邪方对糖尿病肾病大鼠肾组织单核细胞趋化蛋白-1(MCP-1)表达的影响,探讨扶正祛邪方对糖尿病肾病的保护作用及机制。方法:将80只SD大鼠随机分为正常组10只,造模组70只。造模组大鼠予腹腔内注射链脲佐菌素(STZ)进行造模,最后成功建立糖尿病肾病模型大鼠48只,按随机数字表进一步分为模型组、扶正祛邪方组、厄贝沙坦组,每组16只。扶正祛邪方组按16.38 g/(kg·d)的剂量灌胃,厄贝沙坦组按13.5 mg/(kg·d)的剂量灌胃,正常组及模型组灌服等量蒸馏水。给药8周后腹主动脉采血测空腹血糖,收集24 h尿液测尿蛋白,HE染色观察肾组织病理学改变,Western blot检测各组肾组织中MCP-1的表达。结果:治疗前,与正常组比较,模型组的空腹血糖、24 h尿蛋白、MCP-1蛋白显著升高,差异均有统计学意义(P<0.01),说明模型成立。治疗后,与模型组比较,扶正祛邪方组空腹血糖、24 h尿蛋白、MCP-1蛋白显著降低;厄贝沙坦组24 h尿蛋白、MCP-1显著降低,差异均有统计学意义(P<0.01)。治疗后,与治疗前比较,扶正祛邪方组空腹血糖、24 h尿蛋白显著降低;厄贝沙坦组24 h尿蛋白显著降低,差异均有统计学意义(P<0.01)。治疗后,与厄贝沙坦组比较,扶正祛邪方组空腹血糖降低的更明显,差异有统计学意义(P<0.01)。HE染色显示模型组大鼠肾小球体积增大,部分肾小球基底膜增厚,系膜基质增生,肾小管上皮细胞可见空泡样变性,扶正祛邪方组及厄贝沙坦组上述病理改变均明显轻于模型组。结论:扶正祛邪方能降低血糖,改善糖尿病肾病的病理学改变,能下调肾脏MCP-1的表达,起到减少尿蛋白排出,延缓DN进展的作用。 Objective: To observe the effect of Fuzhengquxie prescription on the expression of monocyte chemoattractant protein-1 (MCP-1) in diabetic nephropathy rats and the protective effect of Fuzhengquxue prescription on diabetic nephropathy. Methods: Eighty SD rats were randomly divided into normal group (n = 10) and model group (n = 70). Rats in model group were intraperitoneally injected with streptozotocin (STZ) for modeling. Finally, 48 rats with diabetic nephropathy were successfully established, and randomly divided into model group, Fuzheng Quxie Fang group, Satan group, 16 in each group. Fuzhengquxuefang group was fed at a dose of 16.38 g / (kg · d), irbesartan group at a dose of 13.5 mg / (kg · d), and normal group and model group were given the same amount of distilled water. After 8 weeks of administration, fasting blood glucose was collected from abdominal aorta and urinary protein was collected for 24 hours. The pathological changes of kidney were observed by HE staining. The expression of MCP-1 in renal tissues was detected by Western blot. Results: Before treatment, fasting blood glucose, 24 h urinary protein and MCP-1 protein in model group were significantly higher than those in normal group (P <0.01), indicating that the model was established. After treatment, fasting blood glucose, 24 h urinary protein and MCP-1 protein in Fuzheng Quxie prescription group were significantly lower than those in model group; urinary protein and MCP-1 in 24 hours in irbesartan group were significantly lower, the differences were statistically significant (P <0.01). After treatment, fasting blood glucose and 24-hour urinary protein in Fuzhengquyu Decoction group were significantly decreased compared with those before treatment. Urine protein in 24-hour irbesartan group was significantly lower (P <0.01). After treatment, compared with irbesartan group, Fuzhengquyu Decoction group, fasting blood glucose decreased more significantly, the difference was statistically significant (P <0.01). HE staining showed that glomerular volume increased, part of glomerular basement membrane thickening, mesangial matrix hyperplasia, vacuolar degeneration of renal tubular epithelial cells, Fuzhengquyu Decoction group and irbesartan group Pathological changes were significantly lighter than the model group. CONCLUSION: Fuzhengqudefang can lower blood glucose, improve the pathological changes of diabetic nephropathy, and decrease the expression of MCP-1 in kidney, play a role in reducing urinary protein excretion and retarding the progression of DN.